Patent US6001992A successfully refreshed from Google Patents.
US6001992A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antisense modulation of novel anti-apoptotic bcl-2-related proteins
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1999-01-07
•
Granted: 1999-12-14
•
Expires: 2019-01-07
Abstract
Abstract Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.
Inventors
- 👤 Elizabeth J. Ackermann
- 👤 C. Frank Bennett
- 👤 Nicholas M. Dean
- 👤 Eric G. Marcusson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 19:39
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1135; A; A61; A61P; A61P35/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/318; C12N2310/3181; C12N2310/32; C12N2310/321; C12N2310/33; C12N2310/334; C12N2310/3341; C12N2310/34; C12N2310/341; C12N2310/345; C12N2310/346; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/582
Claims Analysis
Total Claims: 43
Claim 1
Independent Claim
42 words
An antisense compound 8 to 30 nucleobases in length targeted to either SEQ ID NO: 1 or SEQ ID NO: 18, nucleic acid molecules encoding novel anti-apoptotic bcl-2-related proteins, wherein said antisense compound inhibits the expression of said novel anti-apoptotic bcl-2-related proteins.
Claim 2
Dependent Claim
42 words
An antisense compound 8 to 30 nucleobases in length targeted to either SEQ ID NO: 1 or SEQ ID NO: 18, nucleic acid molecules encoding novel anti-apoptotic bcl-2-related proteins, wherein said antisense compound inhibits the expression of said novel anti-apoptotic bcl-2-related proteins.
Claim 3
Dependent Claim
11 words
The antisense compound of claim 1 which is an antisense oligonucleotide.
Claim 4
Dependent Claim
17 words
The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
Claim 5
Dependent Claim
19 words
The antisense compound of claim 3 wherein the modified internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.
Claim 6
Dependent Claim
17 words
The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
Claim 7
Dependent Claim
20 words
The antisense compound of claim 5 wherein the modified sugar moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.
Claim 8
Dependent Claim
16 words
The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
Claim 9
Dependent Claim
15 words
The antisense compound of claim 7 wherein the modified nucleobase is a 2'-O-methoxyethyl modified cytosine.
Claim 10
Dependent Claim
17 words
The antisense compound of claim 8 wherein the modified nucleobase of the antisense oligonucleotide is a 5-methylcytosine.
Claim 11
Dependent Claim
11 words
The antisense compound of claim 1 which is a chimeric oligonucleotide.
Claim 12
Dependent Claim
16 words
The antisense compound of claim 1 which is targeted to a nucleic acid encoding human A1.
Claim 13
Dependent Claim
16 words
The antisense compound of claim 1 which is targeted to a nucleic acid encoding human mcl-1.
Claim 14
Dependent Claim
14 words
A composition comprising the antisense compound of claim 1 and a carrier or diluent.
Claim 15
Dependent Claim
11 words
The composition of claim 13 further comprising a colloidal dispersion system.
Claim 16
Dependent Claim
45 words
A method of inhibiting the expression of a novel human anti-apoptotic bcl-2-related protein in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of said novel human anti-apoptotic bcl-2-related protein is inhibited.
Claim 17
Dependent Claim
19 words
The method of claim 15 wherein the antisense compound is targeted to a nucleic acid molecule encoding human A1.
Claim 18
Dependent Claim
19 words
The method of claim 15 wherein the antisense compound is targeted to a nucleic acid molecule encoding human mcl-1.
Claim 19
Dependent Claim
37 words
A method of promoting apoptosis in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of said novel human anti-apoptotic bcl-2-related protein is inhibited.
Claim 20
Dependent Claim
19 words
The method of claim 18 wherein the antisense compound is targeted to a nucleic acid molecule encoding human A1.
Claim 21
Dependent Claim
19 words
The method of claim 18 wherein the antisense compound is targeted to a nucleic acid molecule encoding human mcl-1.
Claim 22
Dependent Claim
52 words
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid encoding human A1 wherein the antisense compound comprises at least 8 nucleobases of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, and inhibits expression of said human A1.
Claim 23
Dependent Claim
52 words
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid encoding human A1 wherein the antisense compound comprises at least 8 nucleobases of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, and inhibits expression of said human A1.
Claim 24
Dependent Claim
11 words
The antisense compound of claim 21 which is an antisense oligonucleotide.
Claim 25
Dependent Claim
17 words
The antisense compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
Claim 26
Dependent Claim
19 words
The antisense compound of claim 23 wherein the modified internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.
Claim 27
Dependent Claim
17 words
The antisense compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
Claim 28
Dependent Claim
20 words
The antisense compound of claim 25 wherein the modified sugar moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.
Claim 29
Dependent Claim
16 words
The antisense compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
Claim 30
Dependent Claim
15 words
The antisense compound of claim 27 wherein the modified nucleobase is a 2'-O-methoxyethyl modified cytosine.
Claim 31
Dependent Claim
17 words
The antisense compound of claim 28 wherein the modified nucleobase of the antisense oligonucleotide is a 5'-methylcytosine.
Claim 32
Dependent Claim
11 words
The antisense compound of claim 21 which is a chimeric oligonucleotide.
Claim 33
Dependent Claim
43 words
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid encoding human mcl-1 wherein the antisense compound comprises at least 8 nucleobases of SEQ ID NO: 22, 23, 31, 35, or 36, and inhibits expression of said human mcl-1.
Claim 34
Dependent Claim
43 words
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid encoding human mcl-1 wherein the antisense compound comprises at least 8 nucleobases of SEQ ID NO: 22, 23, 31, 35, or 36, and inhibits expression of said human mcl-1.
Claim 35
Dependent Claim
11 words
The antisense compound of claim 31 which is an antisense oligonucleotide.
Claim 36
Dependent Claim
17 words
The antisense compound of claim 32 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
Claim 37
Dependent Claim
19 words
The antisense compound of claim 33 wherein the modified internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.
Claim 38
Dependent Claim
17 words
The antisense compound of claim 32 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
Claim 39
Dependent Claim
20 words
The antisense compound of claim 35 wherein the modified sugar moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.
Claim 40
Dependent Claim
16 words
The antisense compound of claim 32 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
Claim 41
Dependent Claim
15 words
The antisense compound of claim 37 wherein the modified nucleobase is a 2'-O-methoxyethyl modified cytosine.
Claim 42
Dependent Claim
17 words
The antisense compound of claim 38 wherein the modified nucleobase of the antisense oligonucleotide is a 5'-methylcytosine.
Claim 43
Dependent Claim
11 words
The antisense compound of claim 31 which is a chimeric oligonucleotide.
References Cited (Backward Citations)
WO1994029330A1
Cited
WO1995000642A1
Cited
US5646008A
Cited
US5583034A
Cited
WO1996030513A1
Cited
WO1997035971A1
Cited
WO1998005777A2
Cited
US5776905A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-12-13 | 2003-06-14 | 2003-12-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-12-13 | 2007-06-14 | 2007-12-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-12-13 | 2011-06-14 | 2011-12-14 | $7700.00 | Window Closed / Lapsed |